Lupin gets FDA approval for generic Xenazine
The Food and Drug Administration has approved Lupin’s generic Xenazine (tetrabenazine) tablets. The drug is indicated to treat chorea associated with Huntington’s disease.
Lupin’s generic Xenazine will be available in 12.5- and 25-mg dosage strengths. The product had a U.S. market size of roughly $288.1 million for the 12 months ended January 2018, according to IQVIA data.
Lupin’s generic Xenazine will be available in 12.5- and 25-mg dosage strengths. The product had a U.S. market size of roughly $288.1 million for the 12 months ended January 2018, according to IQVIA data.